Title: Effect of pidotimod combined with amoxicillin-clavulanate potassium sequential therapy on symptom improvement and serum CD4+ /CD8+ levels in children with acute tonsillitis
Abstract: Objective
To study the effects of pidotimod combined with amoxicillin-clavulanate potassium sequential therapy on the improvement in symptoms and serum CD4+ /CD8+ levels in children with acute tonsillitis.
Methods
A total of 130 children with acute tonsillitis admitted to Children’s Hospital of Shanxi from April 2017 to April 2018 were enrolled in the study. And they were divided into study group (n=65) and control group (n=65) according to the random number table method. The control group was treated with amoxicillin-clavulanate potassium sequential therapy, and the study group was treated with pidotimod on the basis of treatment for the control group. The treatment effects, clinical symptoms improvement (fever regression, tonsil secretion regression, sore throat disappearance, pharyngeal congestion disappearance), the incidence of adverse reactions, immune function indicators before and after treatment (T lymphocyte subsets, including CD4+ /CD8+ , CD4+ /CD3+ , CD8+ /CD3+ ) and changes in white blood cell count (WBC), C-reactive protein (CRP), and neutrophil percentage (NEUT%) were compared between the two groups.
Results
①The total effective rate of the study group was 98.46% (64/65), which was significantly higher than 86.15% (56/65) of the control group (P 0.05).
Conclusions
Pidotimod combined with amoxicillin-clavulanate potassium sequential therapy can significantly improve the therapeutic effect on children with acute tonsillitis, which can improve the immune function of children, reduce the inflammatory response, and promote the improvement of clinical symptoms. Moreover, it is safe and reliable, and has high application value.
Key words:
Acute tonsillitis; Pidotimod; Amoxicillin-clavulanate potassium; Immune function
Publication Year: 2019
Publication Date: 2019-02-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot